J&J Innovative Medicine Europe, Middle East & Africa (EMEA)

Early action on cancer saves lives - and generates billions. That's the #ValueofHealth

Cancer is not only a health crisis, it’s a macroeconomic one, with an economic burden of €228B across Europe in 2023.² Investing in health protects families, strengthens health systems, and improves Europe’s long-term economic resilience. ²Manzano, A., Svedman, C., Hofmarcher, T. and Wilking, N. (2025) Comparator Report on Cancer in Europe 2025: Disease Burden, Costs and Access to Medicines and Molecular Diagnostics. IHE Report 2025:2. Lund: IHE – The Swedish Institute for Health Economics.

Increased oncological investment can create better outcomes for patients, resilient healthcare systems and thriving economies.² That’s the #ValueofHealth

Lung cancer had the highest financial burden on the EU healthcare system compared to other cancers, eroding an estimated €18.8B from Europe’s economy in one year.² That is why earlier detection and getting innovative treatments to patients sooner can make a real difference for both lives and healthcare budgets. ²Luengo-Fernandez R, et. al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013 Nov;14(12):1165-74. doi: 10.1016/S1470-2045(13)70442-X.

Cancer doesn't stand still. Neither can progress. At #ESMO26, we’re joining the oncology community to explore how earlier diagnosis, more personalised care and continued innovation can help us get #InFrontofCancer, so patients can look beyond cancer to what comes next. Hear Olivia and Pol share what getting in front of cancer can mean for people affected by it, and for those working to change its future. #InFrontofCancer

When discussing severe depression, we often focus on key moments in care: diagnosis, treatment decisions and clinical outcomes. But patients often experience their condition as a journey, perhaps shaped by years of symptoms, multiple treatment attempts, co-existing psychiatric conditions and uncertainty about what comes next. That’s why I believe that better patient-centred care starts with understanding the lived experience of patients, as well as the key moments in their care. Clinical trials remain fundamental to advancing standards of care, but real-world evidence is important in providing a complementary perspective on how treatments are used in routine practice, how diverse patient populations experience care, and how outcomes evolve over time. Research being presented at #ECNP2026 in Munich reinforces the value of evidence that reflects the realities of clinical practice and the long-term experiences of people living with severe depression. For me, the question now is how we put that understanding to work. We need to keep listening to patients, learning from their experiences and bringing those insights into how we think about the future of care. That requires collaboration across the mental health community – and we all have an important role to play.